June 18, 2020 / 5:10 AM / 24 days ago

BRIEF-Roche Holding Says Tecentriq With Chemotherapy Meets Primary Endpoint

June 18 (Reuters) - Roche Holding AG:

* ROCHE’S TECENTRIQ IN COMBINATION WITH CHEMOTHERAPY (INCLUDING ABRAXANE) MEETS PRIMARY ENDPOINT OF IMPROVED PATHOLOGICAL COMPLETE RESPONSE, REGARDLESS OF PD-L1 STATUS, AS INITIAL TREATMENT FOR PEOPLE WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

* IMPASSION031 DATA WILL BE DISCUSSED WITH HEALTH AUTHORITIES GLOBALLY, INCLUDING US FOOD AND DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY

* STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PATHOLOGICAL COMPLETE RESPONSE (PCR) FOR TREATMENT OF PEOPLE WITH EARLY TRIPLE-NEGATIVE BREAST CANCER (TNBC), REGARDLESS OF PD-L1 EXPRESSION

* FEWER PATIENTS WHO RECEIVED TECENTRIQ COMBINATION AS A NEOADJUVANT (BEFORE SURGERY) TREATMENT HAD EVIDENCE OF TUMOUR TISSUE DETECTABLE AT TIME OF SURGERY

* IMPASSION031 STUDY IS SECOND POSITIVE PHASE III STUDY FROM ROCHE Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below